TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00601419

Intervention type: DRUG
Intervention: Somatropin
Description: Genotropin® 12mg for Injection, Genotropin® MiniQuick for s.c. injection 0.6mg, Genotropin® MiniQuick for s.c. injection 1.0mg, Genotropin® MiniQuick for s.c. injection 1.4mg, Genotropin® 5.3mg.~Dosage, Frequency: According to Japanese LPD, The initial dosage is 0.021mg/kg/week as somatropin (genetical recombination) in 6-7 divided doses by s.c. route. The dosage is titrated by 0.084mg/kg/week at a maximum according to the patient's clinical symptoms, and administered in 6-7 divided doses in a week by s.c. route. The dosage may be adjusted according to patient's clinical symptoms and laboratory test results such as serum Insulin-like Growth Factor-I (IGF-I) concentrations. However, the maximum daily dosage shouldn't be higher than 1mg/day.~Duration: According to the protocol of A6281286, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 6 month after the first administration.
Study: NCT03173677

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lipid Intake
Description: 90 grams whipping cream, 31.5 grams fat, 1.7 grams protein, and 2.25 grams carbohydrate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose intake
Description: 300 calories of glucose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein intake
Description: Isopure unflavored Whey proteins isolate (WPI) powder containing 26 grams per serving of 100% WPI, stripped of fat, carbs, fillers, sugars, and lactose
Study: NCT04168333

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: T101 Group
Description: Single Dose (SD) Cohort:~In each group, 3 of chronic hepatitis B patients will be subcutaneously injected with different dose level of T101 at 1.0E+9VP (Group1)/1.0E+10VP (Group2)/1.0E+11VP (Group 3) on D1.~Multiple Dose (MD) Cohort:~In each group, 9 of chronic hepatitis B patients will be subcutaneously injected with different dose level of T101 at 1.0E+10VP (Group1)/1.0E+11VP (Group2) on D1, D8, D15.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: Single Dose (SD) Cohort:~3 of chronic hepatitis B patients will be subcutaneously injected with placebo on D1.~Multiple Dose (MD) Cohort:~6 of chronic hepatitis B patients will be subcutaneously injected with placebo on D1, D8, D15.
Study: NCT03970460

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Primary TKA with cemented modular metal-backed tibial implant
Description: Tibial implant will be done with a cemented implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Primary TKA with cemented modular metal-backed tibial implant
Description: Tibial implant will be done with a cemented implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Primary TKA with uncemented trabecular metal
Description: Tibial implant will be done with a uncemented implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Primary TKA with uncemented trabecular metal
Description: Tibial implant will be done with a uncemented implant
Study: NCT02907164

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Email invitation
Description: Receive emails encouraging them to sign up

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Email invitation
Description: Receive emails encouraging them to sign up

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Email invitation
Description: Receive emails encouraging them to sign up

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Email invitation
Description: Receive emails encouraging them to sign up

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social norm
Description: Receive information about how many people have signed up

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social norm
Description: Receive information about how many people have signed up

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social norm
Description: Receive information about how many people have signed up

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intrinsic, health motive
Description: Receive information about how the challenge helps people to stay fit in a fun way

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extrinsic, reward motive
Description: Receive information about how the challenge helps people to stay active and earn rewards
Study: NCT00824356

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1004723 (200mg)
Description: Intranasal antihistamine.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equivalent to GSK1004723 in presentation etc.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1004723 (1000mg)
Description: Intranasal antihistamine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK1004723 (1000mg)
Description: Intranasal antihistamine.
Study: NCT00971932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: The initial dose of cetuximab will be 400 milligram per square meter (mg/m\^2) as an intravenous (IV) infusion over 120 minutes. Subsequent weekly doses will be 250 mg/m\^2 as an IV infusion over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin/Carboplatin
Description: Subjects will receive 100 mg/m\^2 cisplatin as an IV infusion over 60 minutes on day 1 of each 3-week treatment cycle. If subject developed non-hematological toxicities to cisplatin, carboplatin (area under curve 5 \[AUC5\]) will be administered as an IV infusion over 60 to 120 minutes on Day 1 of each 3-week treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Subjects will receive 1000 mg/m\^2 per day 5-FU as a continuous IV infusion over 24 hours from day 1 to day 4 of each 3-week treatment cycle.
Study: NCT04278040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Inhalations with low doses of Melphalan for 5 consequent days
Study: NCT01664598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: 8 mg/kg administered intravenously (IV) every 4 weeks for 104 weeks
Study: NCT01094860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelarabine
Description: Starting dose 200 mg/m2 for 5 day continuous infusion administered via a central catheter, repeated every 28 days.
Study: NCT02424188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TRIIUMPH Intervention
Description: Group and individual smoking cessation and weight management counseling, pharmacotherapy with varenicline or bupropion and nicotine replacement therapy, group exercise, and text messaging support
Study: NCT00551265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oregovomab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oregovomab
Description: Given IV
Study: NCT01280162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin piperaquine
Description: 40/320 mg tablets, 9 tablets total

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin piperaquine
Description: 40/320 mg tablets, 9 tablets total
Study: NCT00558259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate 150 mg twice daily (BID)
Description: dabigatran etexilate capsules 150 mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo twice daily (BID)
Description: Matching placebo BID
Study: NCT02443090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fispemifene

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01315587

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation (Magstim rapid2 )
Description: * 3 pulses at 50Hz repeated each 200 ms for 2 seconds~* 80% MT~* 20 days treatment
Study: NCT04102098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg will be administered by IV infusion on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
Study: NCT00573508

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin Succinate
Description: Oral Administration
Study: NCT04091555

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: HLNatural Tension
Description: Understand the impact of the supplement on Tension Headaches
Study: NCT03969212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baloxavir Marboxil
Description: IPs less than 12 years old will receive either 2 mg/kg (if weight less than 20 kg) or 40 mg (if weight more than or equal to 20 kg) of Baloxavir Marboxil as oral suspension. IPs more than or equal to 12 years old will receive either 40 mg (if weight less than 80 kg) or 80 mg (if weight more than or equal to 80 kg) of Baloxavir Marboxil as tablets. HHCs of IPs will not receive study medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IPs less than 12 years old will receive placebo oral suspension and those above 12 years will receive placebo tablets. HHCs of IPs will not receive study medication.
Study: NCT02628990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1.6 g plant stanols
Description: Lipid-lowering effect of Yoghurt Drink with 1.6 g plant stanols

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 g plant stanols
Description: Lipid-lowering effect of Yoghurt Drink with 2 g plant stanols

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1.6 g plant stanols and camelina oil
Description: Lipid-lowering effect of Yoghurt Drink with 1.6 g plant stanols and camelina oil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 g plant stanols and camelina oil
Description: Lipid-lowering effect of Yoghurt Drink with 2 g plant stanols and camelina oil

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lipid-lowering effect of Placebo Yoghurt Drink
Study: NCT01720108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban and ASA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rivaroxaban and ASA
Study: NCT01315587

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation (Magstim rapid2)
Description: LDLPFC 110% MT 15 Hz 20 days

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation(Magstim rapid2)
Description: Placebo treatment: Sham coil
Study: NCT00964093

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Silver Alginate
Description: (Algidex ™)
Study: NCT02072161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1002
Description: ETC-1002 capsules, taken once daily oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1002
Description: ETC-1002 capsules, taken once daily oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules, taken once daily oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin Therapy
Description: Patients remained on ongoing statin therapy (not study provided) of either Atorvastatin 10mg or 20mg; Simvastatin 5mg, 10mg or 20mg; Rosuvastatin 5mg or 10mg; or Pravastatin 10mg, 20mg or 40mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin Therapy
Description: Patients remained on ongoing statin therapy (not study provided) of either Atorvastatin 10mg or 20mg; Simvastatin 5mg, 10mg or 20mg; Rosuvastatin 5mg or 10mg; or Pravastatin 10mg, 20mg or 40mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Statin Therapy
Description: Patients remained on ongoing statin therapy (not study provided) of either Atorvastatin 10mg or 20mg; Simvastatin 5mg, 10mg or 20mg; Rosuvastatin 5mg or 10mg; or Pravastatin 10mg, 20mg or 40mg.
Study: NCT01148914

Intervention type: OTHER
Intervention: Inflammatory biomarkers
Description: tTst blood samples for cardiac biomarkers at baseline, 24-hours and 3 month post-ablation
Study: NCT00514891

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A
Description: The effect of vitamin A given with different vaccines will be studied

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin A
Description: The effect of vitamin A given with different vaccines will be studied
Study: NCT02634489

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin HCl
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin Succinate
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EC905
Description: Oral
Study: NCT03276325

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-nalbuphine
Description: Epidural injection of normal saline followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone-nalbuphine
Description: Epidural injection of dexamethasone followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%
Study: NCT01873820

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium ascorbate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium ascorbate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ascorbic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Study: NCT04643522

Intervention type: OTHER
Intervention: Clinical assessment
Description: Comparison of semen analysis results and sex-related hormone levels between the dependent groups which were defined as before COVID-19 and after COVID-19 (the data of the same patient group were compared as before and after the diagnosis of COVID-19).

Intervention type: OTHER
Intervention: Clinical assessment
Description: Comparison of semen analysis results and sex-related hormone levels between the dependent groups which were defined as before COVID-19 and after COVID-19 (the data of the same patient group were compared as before and after the diagnosis of COVID-19).
Study: NCT04223427

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Directional and single ring STN-DBS on gait
Description: Surgery for STN-DBS and STN-LFP recordings during gait initiation (M1): 15 days~* Surgery for STN-DBS electrodes implantation~  * Placement of stimulation electrodes according to the usual procedure, including a MRI with contrast product~ * Intraoperative electrophysiological recordings~ * Intraoperative clinical evaluation~ * Intraoperative identification of the electrodes and final position with X-Ray~ * Post-operative 3D helical TDM without iode injection~* STN-LFP recordings during gait initiation performed 3 to 5 days after surgery~* Placement of the neurostimulator (5 days after surgery)~* Acute testing of STN-DBS for first parameters setting programming~Follow-up of the patient with outpatient visits as usually performed in PD patients operated for STN-DBS with progressive adaptation of parameters settings using single-ring stimulation.~Directional and single ring STN-DBS on gait (M7)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Directional and single ring STN-DBS on gait
Description: Surgery for STN-DBS and STN-LFP recordings during gait initiation (M1): 15 days~* Surgery for STN-DBS electrodes implantation~  * Placement of stimulation electrodes according to the usual procedure, including a MRI with contrast product~ * Intraoperative electrophysiological recordings~ * Intraoperative clinical evaluation~ * Intraoperative identification of the electrodes and final position with X-Ray~ * Post-operative 3D helical TDM without iode injection~* STN-LFP recordings during gait initiation performed 3 to 5 days after surgery~* Placement of the neurostimulator (5 days after surgery)~* Acute testing of STN-DBS for first parameters setting programming~Follow-up of the patient with outpatient visits as usually performed in PD patients operated for STN-DBS with progressive adaptation of parameters settings using single-ring stimulation.~Directional and single ring STN-DBS on gait (M7)
Study: NCT01711723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darapladib 160 mg
Description: Subjects in each group received one tablet orally of Darapladib 160 mg daily for 10 consecutive days. Tablets were taken with food, swallowed whole, not chewed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darapladib 160 mg
Description: Subjects in each group received one tablet orally of Darapladib 160 mg daily for 10 consecutive days. Tablets were taken with food, swallowed whole, not chewed.
Study: NCT00975767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD265+erlotinib
Description: MGCD265 and erlotinib administered daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD265+docetaxel
Description: MGCD265 administered daily; docetaxel administered once every 3 weeks
Study: NCT00545051

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po monthly for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate
Description: 150mg po monthly for 12 months
Study: NCT00557934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dobutamine
Description: dobutamine stress (10 µg/kg/min) for 10 minutes during heart catheterization
Study: NCT02314182

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary tumor resection + chemotherapy
Description: Step 1: Primary Tumor (PT) resection~* Within 3 weeks after randomization~* Immunonutrition given 7 days prior to PT resection~* Mechanical bowel preparation performed before surgery according to the local practices~* Performed by laparoscopy (recommended) or by laparotomy (at the investigator's discretion)~Step 2: postoperative CT-scan~* Must be performed within 4 weeks after surgery~* CT-scan/MRI with the same criteria as pre-treatment evaluation~Step 3: Chemotherapy +/- target therapy~* Within 4 weeks after the surgery~* Chemotherapy administered according to the usual scheme for the chosen protocol~* All validated and/or registered perioperative rectal cancer treatments authorized~* The duration of one treatment cycle depending on the type of treatment administered~* Radiotherapy is allowed after randomization if indicated

Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin/irinotecan + capecitabine, 5-FUI ± bevacizumab
Description: Treatment will start within 3 weeks after randomization; Chemotherapy will be administered according to the regimen in the chosen protocol and validated by the MDOC of each center.~If complications occur, emergency surgery can be performed according to the local practices of each investigator center.~Radiotherapy is allowed after randomization if indicated (MDOC).
Study: NCT00799513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: single-agent lenalidomide 25 mg once daily for 21 days out of 28, as maintenance treatment after the end of second-line chemotherapy until progression of disease.
Study: NCT01234753

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Physician and nurse consultation
Description: Usual care by a visit to physician at the hospital out-patient clinic and computer-based and individual education and psychosocial support by a nurse-led session.
Study: NCT00728611

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRGF
Description: intra auricular injection 6mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyaluronic acid
Description: 20 mg / 2 ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: physiological water 3cc + lidocain 3cc
Study: NCT03972254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Interaction Guidance
Description: The main steps in the procedure are to have the family identify the primary concern they are facing, highlight the strengths that the family already has in place and expand on those strengths, convey/impart caregiving and societal norms, and offer other perspectives (McDonough, 2004). The goal of this therapy is to engage the family to take an active role in the construction of their overall treatment. The individualized treatment approach focuses and builds on existing strengths.
Study: NCT03690232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucose water
Description: 3 sessions of 6cc 25% glucose injection with a 2-week interval

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyaluronic aicd
Description: intra-articular HA ((Hyruan Plus® , average MW 3000 kD; LG Life Sciences Ltd, Korea)) for sessions with a 1-week interval between each treatment
Study: NCT01248065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: vitamin D (100,000 IU loading dose followed by 4,000 IU/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclesonide
Description: Low dose inhaled corticosteroid (80 mcg/puff two puffs twice daily)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ciclesonide
Description: Low dose inhaled corticosteroid (80 mcg/puff two puffs twice daily)
Study: NCT00893984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Bystolic (Nebivolol), 5 mg per day for 30 days, titrated up to 10 mg at 2 weeks if necessary for blood pressure control.
Study: NCT04331145

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 60mg
Description: Platelet reactivity will be assessed by VerifyNow P2Y12 assay in ALL enrolled patients after confirmed use of clopidogrel for 4 days prior TAVI. Patients that have not completed a pre-treatment period of 4 days of clopidogrel will receive a loading dose of 300mg, according to the clinical practice, with assessment of platelet reactivity by VerifyNow P2Y12 at the following 6 hours. Based on results of basal VerifyNow P2Y12 assay at least 24 hours before the index-TAVI procedure, patients with:~High on-treatment platelet reactivity (PRU ≥ 160 assessed with VerifyNow P2Y12 assay): Patients will be switched to receive ticagrelor 60mg twice daily initiating at least 24hrs before TAVI procedure, in order to arrive to the index TAVI procedure with at least two doses of 60 mg, and will continue with Ticagrelor 60mg twice per day during the following three months.
Study: NCT02487732

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor 90mg twice daily for 5 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Prasugrel 10mg once daily for 5 weeks